Video and Slides - Treat or No Treat:Treatment Decisions for CHB

[Guest guest]

Having trouble viewing this email? Click here

http://campaign.r20.constantcontact.com/render?llr=udefsxdab & v=001ZxTRMtTNNkgOug\

P2iMsVx2f5zyfQYCfch6zAKIIRlokEiC6RtRTV7w3DsQPsK86mSigj0NdbOO9jSWrnbPVn0IDY-Vexyv\

sCw4KXa0gOmEk%3D

Release Date: December 3, 2010

Expiration Date: December 3, 2011

New Video and Slides - Treat or No Treat:

A Case-based Discussion Considering

Evidence and Expert Insights

in Treatment Decisions for CHB

Faculty

Program Chair

Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF

Leonard Professor of Medicine

Director, Schiff Liver Institute

Director, Center for Liver Diseases

Division of Hepatology

Miami, FL

Mark Sulkowski, MD

Associate Professor of Medicine

Medical Director, Viral Hepatitis Center

s Hopkins University School of Medicine

Baltimore, MD

Gish, MD

Professor of Clinical Medicine

Co-director, CHAT

Chief of Clinical Hepatology

University of California,

San Diego Medical Center

San Diego, CA

Tram T. Tran, MD

Associate Professor of Medicine

Geffen UCLA School of Medicine

Medical Director

Liver Transplant Program

Cedars-Sinai Medical Center

Los Angeles, CA

PROGRAM OVERVIEW

Chronic hepatitis B (CHB) continues to be a significantly untreated disease in

the United States. Two-thirds of the estimated 1.25 million hepatitis B carriers

in the United States do not know they are infected and are unlikely to discover

their status until they show signs of potentially life-threatening illnesses.

rs of hepatitis B virus (HBV) are at increased risk for developing

cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC), with 15%

to 40% developing these serious hepatic complications in their lifetime. There

is an urgent need to screen, diagnose, and treat CHB to prevent further spread

and reduce morbidity and mortality associated with CHB.

During this case-based video and slide presentation, experts will discuss the

significant advances that have been made in the past 5 years in our

understanding of the natural history of hepatitis B and the management of

patients with CHB. In addition, the 2009 American Association for the Study of

Liver Diseases (AASLD) Practice Guidelines and the most recent European

Association for Study of the Liver (EASL) Clinical Practice Guidelines will be

examined. Pregnancy in the patient with CHB also presents the provider with a

unique set of management challenges which will be addressed by the Faculty.

These include maternal and fetal effects of hepatitis B, effects of pregnancy

itself on the course of hepatitis B infection and its complications, treatment

of hepatitis B during pregnancy, and prevention of perinatal infection. In

addition, patients with hepatitis B undergoing immunosuppressive or cancer

chemotherapy present a different set of challenges for the provider, including

prophylactic antiviral therapy and timing of initiation of chemotherapy. These

challenges, among others, will be addressed in terms of the 2009 AASLD Practice

Guidelines and the 2010 American Society of Clinical Oncology Clinical Practice

Guidelines.

TARGET AUDIENCE

This activity is designed for hepatologists and gastroenterologists who treat

patients with CHB.

EDUCATIONAL OBJECTIVES

Upon completing this program, participants will be better able to:

•

Integrate the 2009 AASLD Practice Guidelines into clinical practice with respect

to screening at-risk patients, treatment timing, selection of agents and

duration of treatment

•

Develop treatment strategies for the management of pregnant women with CHB and

for the prevention of perinatal infection in newborns

•

Develop management strategies for HBV carriers undergoing immunosuppressive or

cytotoxic therapy

PHYSICIAN CONTINUING MEDICAL EDUCATION

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential

Areas and policies of the Accreditation Council for Continuing Medical Education

(ACCME) through the joint sponsorship of Postgraduate Institute for Medicine

(PIM) and HealthmattersCME. PIM is accredited by the ACCME to provide continuing

medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a

maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim

credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners,

managers, and other individuals who are in a position to control the content of

this activity to disclose any real or apparent conflict of interest they may

have related to the content of this activity. All identified conflicts of

interest are thoroughly vetted by PIM for fair balance, scientific objectivity

of studies mentioned in the materials or used as the basis for content, and

appropriateness of patient care recommendations.

METHOD OF PARTICIPATION/HOW TO OBTAIN CME CREDIT

There are no fees for participating and receiving CME credit for this activity.

During the period December 3, 2010 through December 3, 2011, participants must

(1) read the learning objectives and faculty disclosures; (2) study the

educational activity; (3) complete the posttest by going to

http://www.cmeuniversity.com to register or login, click on " Find Post-tests by

Course " on the navigation menu, select Course 7585, and recording the best

answer to each question; and (4) complete the evaluation form and credit

request. A statement of credit will be issued only upon receipt of a completed

activity evaluation form and a completed posttest with a score of 70% or better.

Media

Internet Activity

This webcast requires a broadband Internet connection, Flash Player 8 or

greater, (optional) sound card and speakers for audio.

This activity is jointly sponsored by Postgraduate Institute for Medicine and

HealthmattersCME.

This activity is supported by an independent educational grant from Gilead

Sciences Medical Affairs.

Forward email

This email was sent to shereemartin@... by newsletter@....

Update Profile/Email Address | Instant removal with SafeUnsubscribe™ | Privacy

Policy.

Email Marketing by

HIVandHepatitis.com | P.O. Box 2010 | San Francisco | CA | 94114